Galectin Therapeutics, Inc. (GALT) Analysts See $-0.11 EPS

March 15, 2018 - By Louis Casey

 Galectin Therapeutics, Inc. (GALT) Analysts See $ 0.11 EPS
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Moreover, Bancorp Of New York Mellon Corporation has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Susquehanna International Grp Llp, Pennsylvania-based fund reported 168,648 shares. Da Davidson Com holds 0.03% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 690,960 shares. Schwab Charles Inv Mngmt owns 21,400 shares. Vanguard Incorporated invested in 850,948 shares. Stratos Wealth Partners has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Wells Fargo Mn reported 11,882 shares. Norris Perne And French Llp Mi holds 30,500 shares. Courage Management Lc reported 130,000 shares or 0.19% of all its holdings. Benchmark Advsr accumulated 194,200 shares. Geode Cap Mgmt Limited Liability reported 195,411 shares or 0% of all its holdings. State Street holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 11,450 shares. Morgan Stanley reported 0% stake. Tiedemann Wealth Mgmt Llc holds 15,000 shares. First Republic Investment Management owns 26,000 shares for 0% of their portfolio.

Since January 25, 2018, it had 2 insider buys, and 2 insider sales for $2.64 million activity. 244,444 shares were sold by 10X Fund – L.P., worth $1.33 million on Thursday, January 25. CZIRR JAMES C also sold $1.33 million worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 29 before the open.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 8.29% or $0.43 during the last trading session, reaching $4.76. About 376,023 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 14 by H.C. Wainwright. The stock has “Sell” rating by Roth Capital on Wednesday, September 28. H.C. Wainwright initiated Galectin Therapeutics, Inc. (NASDAQ:GALT) on Monday, September 21 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Thursday, December 7. The rating was maintained by Roth Capital with “Buy” on Thursday, January 4. The company was downgraded on Wednesday, September 28 by TH Capital. H.C. Wainwright reinitiated Galectin Therapeutics, Inc. (NASDAQ:GALT) on Monday, March 28 with “Buy” rating. The firm has “Neutral” rating given on Thursday, September 29 by H.C. Wainwright. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) has “Mkt Perform” rating given on Monday, October 3 by FBR Capital. H.C. Wainwright upgraded Galectin Therapeutics, Inc. (NASDAQ:GALT) on Thursday, March 30 to “Buy” rating.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $172.02 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics Granted Patents in China and Japan that Support NASH and …” on January 25, 2018, also with their article: “Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting …” published on March 05, 2018, published: “Galectin Therapeutics Reports 2017 Third Quarter Financial Results and …” on November 07, 2017. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics to Present at Two International Conferences in March” published on March 09, 2018 as well as‘s news article titled: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.